These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 12455829)

  • 1. Synthesis of RGD containing peptides and their bioactivities.
    Zhao M; Wang C; Jiang X; Pen S
    Prep Biochem Biotechnol; 2002 Nov; 32(4):363-80. PubMed ID: 12455829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and bioactivities of nitronyl nitroxide and RGD containing pseudopeptides.
    Liu J; Zhao M; Wang C; Peng S
    Bioorg Med Chem Lett; 2003 Nov; 13(22):4065-9. PubMed ID: 14592509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and antithrombotic activity of carbolinecarboxyl RGD sequence.
    Lin N; Zhao M; Wang C; Peng S
    Bioorg Med Chem Lett; 2002 Feb; 12(4):585-7. PubMed ID: 11844677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Studies on the synthesis and activities of RGD related peptides].
    Zhao M; Peng SQ; Dilinuer S; Wang YY; Zhou QL; Zhao WZ
    Yao Xue Xue Bao; 1997 Apr; 32(4):271-7. PubMed ID: 11499029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of arginine-glycine-aspartate-containing peptides as inhibitors of equine platelet function.
    Weiss DJ; Evanson OA; Wells RE
    Am J Vet Res; 1997 May; 58(5):457-60. PubMed ID: 9140550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biological activity of synthetic analogs of laminin active sequences: YIGSR, RGD, SIKVAV].
    Hill-Bator A; Opolski A
    Postepy Hig Med Dosw; 2002; 56(5):579-88. PubMed ID: 12587426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disintegrins: RGD-containing proteins which inhibit cell/matrix interactions (adhesion) and cell/cell interactions (aggregation) via the integrin receptors.
    Williams JA
    Pathol Biol (Paris); 1992 Oct; 40(8):813-21. PubMed ID: 1484742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model.
    Cadroy Y; Houghten RA; Hanson SR
    J Clin Invest; 1989 Sep; 84(3):939-44. PubMed ID: 2760221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and antiaggregatory activity of RGD-peptidomimetics based on 4-oxo-4-(piperazine-1-yl)butyric acid as Arg-mimetic.
    Andronati SA; Krysko AA; Kabanov VM; Kabanova TA; Karaseva TL; Chugunov BM; Meshkova SB; Topilova ZM
    Acta Pol Pharm; 2003; 60(5):375-81. PubMed ID: 15005421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of RGD containing peptides and their vasodilation effect.
    Ming Z; Chao W; Jian Y; Shiqi P
    Prep Biochem Biotechnol; 2000 Aug; 30(3):247-56. PubMed ID: 10919564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and cell attachment activity of bioactive oligopeptides: RGD, RGDS, RGDV, and RGDT.
    Hirano Y; Kando Y; Hayashi T; Goto K; Nakajima A
    J Biomed Mater Res; 1991 Dec; 25(12):1523-34. PubMed ID: 1724445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferred conformations of RGDX tetrapeptides to inhibit the binding of fibrinogen to platelets.
    Park HS; Kim C; Kang YK
    Biopolymers; 2002 Apr; 63(5):298-313. PubMed ID: 11877740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2-antiplasmin) enhances plasminogen binding to platelets.
    Udvardy M; Schwartzott D; Jackson K; Posan E; Rak K; McKee PA
    Blood Coagul Fibrinolysis; 1995 Jul; 6(5):481-5. PubMed ID: 8589217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel potent peptidyl platelet preserving agent: molecular design and biologic activity.
    Ozeki E; Matsuda T
    ASAIO Trans; 1990; 36(3):M562-4. PubMed ID: 2252751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749).
    Nicholson NS; Panzer-Knodle SG; Salyers AK; Taite BB; King LW; Miyano M; Gorczynski RJ; Williams MH; Zupec ME; Tjoeng FS
    J Pharmacol Exp Ther; 1991 Mar; 256(3):876-82. PubMed ID: 2005585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta 3 integrin derived peptide 217-230 inhibits fibrinogen binding and platelet aggregation: significance of RGD sequences and fibrinogen A alpha-chain.
    Lasz EC; McLane MA; Trybulec M; Kowalska MA; Khan S; Budzynski AZ; Niewiarowski S
    Biochem Biophys Res Commun; 1993 Jan; 190(1):118-24. PubMed ID: 8422238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Function of fibrinogen gamma-chain dodecapeptide-conjugated latex beads under flow.
    Takeoka S; Okamura Y; Teramura Y; Watanabe N; Suzuki H; Tsuchida E; Handa M; Ikeda Y
    Biochem Biophys Res Commun; 2003 Dec; 312(3):773-9. PubMed ID: 14680832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of RGD-containing peptides on platelet aggregation].
    Vasil'eva TM; Makarov VA; Petrukhina GN; Voiushina TL; Iusupova MP; Novgorodova SA; Kotlova EK
    Eksp Klin Farmakol; 2006; 69(4):39-42. PubMed ID: 16995437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimized conventional synthesis of "RGD" and "RGDS" peptides and their sarcosine mimics as integrin GP IIb/IIIa antagonists.
    Abo-Ghalia M; Abd El-Rahman S; El-Kafrawy A; Kalomuch A
    Amino Acids; 2003 Jun; 24(4):405-11. PubMed ID: 12768503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system.
    Gupta AS; Huang G; Lestini BJ; Sagnella S; Kottke-Marchant K; Marchant RE
    Thromb Haemost; 2005 Jan; 93(1):106-14. PubMed ID: 15630499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.